Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

Explaining racial disparities in anticoagulation control: results from a study of patients at the Veterans Administration.

Rao SR, Reisman JI, Kressin NR, Berlowitz DR, Ash AS, Ozonoff A, Miller DR, Hylek EM, Zhao S, Rose AJ.

Am J Med Qual. 2015 May;30(3):214-22. doi: 10.1177/1062860614526282. Epub 2014 Mar 18.

PMID:
24642366
2.

Where You Live Matters: Quality and Racial/Ethnic Disparities in Schizophrenia Care in Four State Medicaid Programs.

Horvitz-Lennon M, Volya R, Garfield R, Donohue JM, Lave JR, Normand SL.

Health Serv Res. 2015 Oct;50(5):1710-29. doi: 10.1111/1475-6773.12296. Epub 2015 Mar 11.

3.

Pathways to poor anticoagulation control.

Razouki Z, Ozonoff A, Zhao S, Rose AJ.

J Thromb Haemost. 2014 May;12(5):628-34. doi: 10.1111/jth.12530.

4.

Racial disparities in diabetes care processes, outcomes, and treatment intensity.

Heisler M, Smith DM, Hayward RA, Krein SL, Kerr EA.

Med Care. 2003 Nov;41(11):1221-32.

PMID:
14583685
5.

Quality of anticoagulation with warfarin in patients with nonvalvular atrial fibrillation in the community setting.

Han SY, Palmeri ST, Broderick SH, Hasselblad V, Rendall D, Stevens S, Tenaglia A, Velazquez E, Whellan D, Wagner G, Heitner JF.

J Electrocardiol. 2013 Jan-Feb;46(1):45-50. doi: 10.1016/j.jelectrocard.2012.08.011. Epub 2012 Oct 11.

PMID:
23063241
6.

Patient characteristics associated with oral anticoagulation control: results of the Veterans AffaiRs Study to Improve Anticoagulation (VARIA).

Rose AJ, Hylek EM, Ozonoff A, Ash AS, Reisman JI, Berlowitz DR.

J Thromb Haemost. 2010 Oct;8(10):2182-91. doi: 10.1111/j.1538-7836.2010.03996.x.

7.

Use of mechanical and noninvasive ventilation in black and white chronic obstructive pulmonary disease patients within the Veterans Administration health care system.

Cannon KT, Sarrazin MV, Rosenthal GE, Curtis AE, Thomas KW, Kaldjian LC.

Med Care. 2009 Jan;47(1):129-33. doi: 10.1097/MLR.0b013e3181809150.

PMID:
19106742
8.

Racial Differences in Quality of Anticoagulation Therapy for Atrial Fibrillation (from the TREAT-AF Study).

Yong C, Azarbal F, Abnousi F, Heidenreich PA, Schmitt S, Fan J, Than CT, Ullal AJ, Yang F, Phibbs CS, Frayne SM, Ho PM, Shore S, Mahaffey KW, Turakhia MP.

Am J Cardiol. 2016 Jan 1;117(1):61-8. doi: 10.1016/j.amjcard.2015.09.047. Epub 2015 Oct 22.

PMID:
26552504
9.

Prompt repeat testing after out-of-range INR values: a quality indicator for anticoagulation care.

Rose AJ, Hylek EM, Berlowitz DR, Ash AS, Reisman JI, Ozonoff A.

Circ Cardiovasc Qual Outcomes. 2011 May;4(3):276-82. doi: 10.1161/CIRCOUTCOMES.110.960096. Epub 2011 Apr 19.

10.

Predicting outcomes among patients with atrial fibrillation and heart failure receiving anticoagulation with warfarin.

Kim EJ, Ozonoff A, Hylek EM, Berlowitz DR, Ash AS, Miller DR, Zhao S, Reisman JI, Jasuja GK, Rose AJ.

Thromb Haemost. 2015 Jul;114(1):70-7. doi: 10.1160/TH14-09-0754. Epub 2015 May 7.

PMID:
25948532
11.

Comparing patient-level and site-level anticoagulation control as predictors of adverse events.

Cancino RS, Hylek EM, Reisman JI, Rose AJ.

Thromb Res. 2014 Apr;133(4):652-6. doi: 10.1016/j.thromres.2014.01.013. Epub 2014 Jan 14.

PMID:
24502961
12.

Racial disparities in awareness and treatment of atrial fibrillation: the REasons for Geographic and Racial Differences in Stroke (REGARDS) study.

Meschia JF, Merrill P, Soliman EZ, Howard VJ, Barrett KM, Zakai NA, Kleindorfer D, Safford M, Howard G.

Stroke. 2010 Apr;41(4):581-7. doi: 10.1161/STROKEAHA.109.573907. Epub 2010 Feb 26.

13.

Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKET AF clinical trial.

Singer DE, Hellkamp AS, Piccini JP, Mahaffey KW, Lokhnygina Y, Pan G, Halperin JL, Becker RC, Breithardt G, Hankey GJ, Hacke W, Nessel CC, Patel MR, Califf RM, Fox KA; ROCKET AF Investigators.

J Am Heart Assoc. 2013 Feb 19;2(1):e000067. doi: 10.1161/JAHA.112.000067.

14.

Improving quality measurement for anticoagulation: adding international normalized ratio variability to percent time in therapeutic range.

Razouki Z, Ozonoff A, Zhao S, Jasuja GK, Rose AJ.

Circ Cardiovasc Qual Outcomes. 2014 Sep;7(5):664-9. doi: 10.1161/CIRCOUTCOMES.114.000804. Epub 2014 Sep 2.

15.

Race- and sex-related differences in care for patients newly diagnosed with atrial fibrillation.

Bhave PD, Lu X, Girotra S, Kamel H, Vaughan Sarrazin MS.

Heart Rhythm. 2015 Jul;12(7):1406-12. doi: 10.1016/j.hrthm.2015.03.031. Epub 2015 Mar 23.

16.

Application of the nonlinear Blinder-Oaxaca decomposition to study racial/ethnic disparities in antiobesity medication use in the United States.

Mehta HB, Rajan SS, Aparasu RR, Johnson ML.

Res Social Adm Pharm. 2013 Jan-Feb;9(1):13-26. doi: 10.1016/j.sapharm.2012.02.006. Epub 2012 May 2.

PMID:
22554395
18.

Bleeding rates in Veterans Affairs patients with atrial fibrillation who switch from warfarin to dabigatran.

Vaughan Sarrazin MS, Jones M, Mazur A, Chrischilles E, Cram P.

Am J Med. 2014 Dec;127(12):1179-85. doi: 10.1016/j.amjmed.2014.07.024. Epub 2014 Aug 12.

PMID:
25107386
19.

Racial differences in the prevalence and outcomes of atrial fibrillation among patients hospitalized with heart failure.

Thomas KL, Piccini JP, Liang L, Fonarow GC, Yancy CW, Peterson ED, Hernandez AF; Get With the Guidelines Steering Committee and Hospitals.

J Am Heart Assoc. 2013 Sep 26;2(5):e000200. doi: 10.1161/JAHA.113.000200.

20.

Racial disparities in the use of revascularization before leg amputation in Medicare patients.

Holman KH, Henke PK, Dimick JB, Birkmeyer JD.

J Vasc Surg. 2011 Aug;54(2):420-6, 426.e1. doi: 10.1016/j.jvs.2011.02.035. Epub 2011 May 14.

Supplemental Content

Support Center